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Aim/background: To evaluate how the use of volumetric-modulated arc therapy (VMAT) with
RapidArc® can improve treatment delivery efﬁciency based on the analysis of the beam-on
times and monitor units (MU) needed to deliver therapy for multiple clinical applications in
a  large patient population.
Materials and methods: A total of 898 treatment courses were delivered in 745 patients treated
from October 2008 to March 2013 using RapidArc® treatment plans generated in EclipseTM
TPS. All patients were treated with curative or palliative intent using different techniques
including conventional fractionation (83%) and radiosurgery or SBRT (17%), depending on
the clinical indications. Treatment delivery was evaluated based on measured beam-on time
and  recorded MU values delivered on a Varian TrilogyTM linear accelerator.
Results: For conventional fractionation treatments using RapidArc®, the delivery times
ranged from 38 s to 4 min and 40 s (average 2 min and 6 s). For radiosurgical treatments
the  delivery times ranged from 1 min and 42 s to 9 min and 22 s (average 4 min  and 4 s). The
average number of MU per Gy was 301 for the entire group, with 285 for the conventional
group and 317 for the radiosurgical group.
Conclusions: In this study with a large heterogeneous population, treatments using
RapidArc® were delivered with substantially less beam-on time and fewer MUs  than conven-
tional fractionation. This was highly advantageous, increasing ﬂexibility of the scheduling
allowing treatment of radiosurgery patients during the regular daily work schedule. Addi-
tionally, reduction of leakage radiation dose was achieved.
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Table 1 – Total number of RapidArc® treatment
courses/site.
Site/diagnosis No. treatment courses
Prostate 156
Gynecological 137
Lung 106
H/N 91
Spine 87
Pelvis 87
Brain 60
Abdomen 58
Chest 19
Breast 18
Liver 18
Rectum 17
Skin 15
Bladder 11
Pancreas 10
Esophagus 8
Total 898
Table 2 – Range and average values of beam-on time for
conventional fractionation and SRS/SBRT using
RapidArc®.
Beam-on time Conventional SRS/SBRT
Min 0.63 1.7384  reports of practical oncology an
1.  Introduction
1.1.  Background
RapidArc® (Varian Medical Systems, Palo Alto, CA) is a novel
technique developed to deliver highly focused volumetric-
modulated arc therapy6 approved for clinical use in 2008 [1].
The basic concept of arc therapy is the delivery of radiation
from a continuous rotation of the radiation source. In the case
of RapidArc® it delivers a precisely sculpted 3D dose distri-
bution with a 360◦ rotation of the accelerator gantry made
possible by a treatment planning algorithm that varies simul-
taneously 3 parameters during treatment: (1) gantry rotation
speed, (2) treatment aperture shape using the movement  of
multileaf collimator leaves and (3) delivery dose rate [2]. This
technique can achieve highly conformal dose distributions
with improved target volume coverage and sparing of normal
tissues compared with conventional radiotherapy techniques.
In addition, it also has the potential to offer reduced treatment
delivery time and less MUs  compared with conventional static
ﬁeld intensity modulated radiotherapy.7
In the case of radiosurgery, delivery of high-dose-per-
fraction SRS or SBRT with multi-ﬁeld IMRT can be highly
time-consuming because of the many  beam angles required to
conform to the target shape and the large number of monitor
units8 needed to deliver the dose [3].
In this retrospective review we analyze the beam-on times
and MU  per fraction needed to deliver therapy with RapidArc®
at several sites in a large patient population of multiple clinical
applications including conventional fractionation and radio-
surgery/SBRT.
2.  Materials  and  methods
From October 2008 to March 2013 a total of 745 patients
received 898 treatment courses using RapidArc®: 749 (83%)
with conventional fractionation and 149 (17%) with radio-
surgery/SBRT. Diagnosis and treatment sites characteristics
are shown in Table 1. For conventional RapidArc® the num-
ber of arcs ranged from 1 to 5, but most frequently 2 arcs
were used. For RapidArc® Radiosurgery/SBRT the number of
arcs ranged from 2 to 6 depending on the size, location, and
volume of the target. Partial arcs and multiple coplanar/non-
coplanar arcs were used depending on the case speciﬁcation
(see Table 2).
Patient speciﬁc quality assurance9 was performed prior to
ﬁrst day of treatment delivery using a XWU-IMRT Phantom
(Best Medical Canada Ltd.) with MOSFETS and ﬁlm dosime-
try and/or the ArcCHECK® System (Sun Nuclear Corporation).
Dose agreement was within 3%.Patients were selected for RapidArc® following the same
indications as conventional IMRT:  anytime that critical struc-
ture protection required the creation of complex dose
6 Volumetric-modulated arc therapy (VMAT).
7 Intensity modulated radiotherapy (IMRT).
8 Monitor unit (MU).
9 Quality assurance (QA).Max 4.68 9.36
Average 2.08 4.06
distributions; if the target volume was irregularly shaped and
in close proximity to critical structures that needed to be
protected, the volume of interest was covered with narrow
margins to adequately protect immediately adjacent struc-
tures; an immediately adjacent area that had been previously
irradiated and abutting portals were established with high pre-
cision in all cases of salvage radiation. Several fractionation
schemes were used depending on the indications. One, 3, or 5
fractions were delivered in radiosurgery/SBRT, and anywhere
from 15 to 45 daily fractions for conventional regimens. In gen-
eral for conventional treatments, shorter schemes where used
for palliative cases and longer ones for curative intent.
All patients were treated using a TrilogyTM Linear accelera-
tor (Varian Medical Systems, Palo Alto, CA) with energies of 6 or
16 MV and a 120 multi-leaf collimator, planned with EclipseTM
system using inverse treatment planning. Cone Beam CT
(CBCT)10 was used daily for image  guidance before delivering
the treatment.
For treatment planning, CT simulation was acquired
with various immobilization devices including customized
Aquaplast and body-frame. For head and neck, thoracic and
CNS tumors IV contrast was routinely used to aid tumor delin-
eation unless contraindicated. The gross and/or clinical tumor
11,12volume were deﬁned using CT, MRI, and/or PET/CT. MRI
was used in most CNS and in GYN patients unless contraindi-
cated. PET/CT was generally used, particularly for lung and
10 Cone Beam CT (CBCT).
11 Gross tumor volume (GTV).
12 Clinical tumor volume (CTV).
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hig. 1 – Beam-on times for all patients treated in our center 
onventional fractionation and SRS/SBRT, respectively. The t
ead and neck tumors. RTOG guidelines for treatment and
ormal tissue constrains were used.
For comparison purposes, we reviewed the data of a group
f 19 patients who were treated with conventional IMRT  in
ur institution prior to the implementation of the RapidArc®
ystem.
The treatment time and MUs  for every treatment were
xtracted from the patients’ electronic medical record in
RIA®.
Fig. 1.
.  Results
hen using RapidArc® for conventional treatments, the deliv-
ry times ranged from 38 s to 4 min  and 40 s (average 2 min
nd 6 s). For radiosurgical/SBRT treatments using RapidArc®
he delivery times ranged from 1 min  and 42 s to 9 min  and
2 s (average 4 min  and 4 s). Due to the short treatment time
here was no need to signiﬁcantly modify the schedule when
adiosurgery/SBRT procedures were performed. The average
umber of MUs  per Gy was 301 for the entire group, with
85 for the conventional group and 317 for the radiosurgical
roup. Acute toxicity was minimal even in patients undergo-
ng systemic chemotherapy. In the conventional IMRT group,
2 patients were treated for prostate cancer, 4 for head and
eck cancer, and 3 for lung cancer. The comparison of these
roups as seen in Fig. 2 showed that MUs  were reduced by 45%
n prostate cancer, 58% in head and neck cancer, and 39% in
ung cancer.
ig. 2 – Comparison of the average number of MUs  in
atients treated with RapidArc® and IMRT  for prostate,
ead and neck, and lung cancer in our institution. RapidArc . The orange and blue points show the times for
range and average is shown in Table 2.
4.  Discussion
IMRT  represented a signiﬁcant advance in conformal Radio-
therapy allowing the delivery of dose distributions with
complex isodose proﬁles as reported in 2000 by Nutting et al.
[4].
The advantages of this technique were clearly demon-
strated in early reports particularly in head and neck cancer
cases where sparing of the salivary glands was successfully
accomplished. IMRT provides better dose distribution in the
target volume and lower dose for organs at risk, such as for
the parotid glands [5].
However, a good conventional IMRT  often requires more
ﬁxed ﬁelds with higher MUs, resulting in lengthy treatment
delivery times. The development of RapidArc® software has
included many  of the IMRT  beneﬁts, but given in shorter
treatment times. In a recently published study, 20 patients
with nasopharyngeal tumors treated by Zheng et al. [6] using
RapidArc® showed better dosimetry compared with con-
ventional IMRT. In their study, two treatment plans were
developed for each patient, one with RapidArc® and the other
with ﬁxed 9-ﬁeld coplanar dynamic IMRT.  The EclipseTM sys-
tem was used for both plans with 6 MV-energy and a 120
multi-leaf collimator. The mean treatment time of RapidArc®
and IMRT was 165 versus 447 s. The mean MU  values of
RapidArc® and IMRT were 550 and 1379 respectively. Compar-
ing to IMRT,  the delivery time and the MU  values of RapidArc®
were reduced by 63% and 60%, respectively [6] In the case of
prostate cancer treated with RapidArc®, Yoo et al. [7] recently
reported a reduction of MUs ranging from 37% to 66% depend-
ing on the number of arcs and the primary and boost plan.
With the comparable equipment, our experience is in agree-
ment with both of these studies: the reduction in MUs  was
58% for head and neck cancer and 45% for prostate cancer in
our patient population treated with RapidArc®.
We reviewed our preliminary data in intrathoracic tumors
from October 2008 to March 2012. Eighty-one treatment
courses in 62 patients with thoracic tumors: 53 using conven-
tional fractionation, 25 using SBRT, and in 3 patients for Lattice
Radiation Therapy. In conventional fractionation planning we
used between 1 and 4 arcs, mostly 2 arcs. The dose per fraction
ranged from 1.8 Gy to 3 Gy. The average number of MUs  per
Gy was 260. Treatment times ranged from 1.1 min  to 2.9 min
depending on the total arc length. For SBRT, 4 non-coplanar
partial arcs were typically used. The number of arcs ranged
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radiotherapy for peripheral lung tumors: a comparison of
volumetric modulated arc therapy with 3 other delivery
techniques. Radiother Oncol 2010;97(December (3)):437–42, doi:386  reports of practical oncology an
from 1 to 6. An average of 330 MU/Gy was resulted and the
“beam-on” time ranged from 2.2 to 10.3 min  depending on
the number of MUs  used. Dose per fraction ranged from 5 to
20 Gy given in 1–5 fractions. Acute toxicity was minimal for all
the patients. No interruptions during the course of treatment
occurred for patients who had a high Karnofsky score and the
treatments were well tolerated. Reproducibility of the patient
setup was achieved using IGRT/CBCT. The shorter treatment
time eased patient’s tolerance and minimized movement
during treatment. No acute toxicity was encountered in this
series of patients treated with RapidArc® [8].
In Ong et al’s study of stereotactic radiotherapy for periph-
eral lung tumors the average MUs  per Gy was 240 with VMAT
versus 445 with IMRT  [9]. This is close to our results of 330 MU
per Gy for SRS/SBRT patients using RapidArc®. Our compari-
son of lung conventional fractionation with RapidArc® versus
IMRT  resulted in an average reduction from 425 MU/Gy with
IMRT  to 260 MU/Gy with RapidArc®.
Rapid delivery of SRS and SBRT with RapidArc® improves
workﬂow on the Linac and minimizes the potential for
intrafraction organ and patient motion.
5.  Conclusions
In this study of a large heterogeneous population using
RapidArc®, substantially less beam-on time and fewer MUs
than conventional fractionation were observed. Our results
support several beneﬁts including reduction of leakage radi-
ation dose with potential decrease of risk of secondary
malignancies, less intra-fraction movement  and more  accu-
rate treatment delivery. The treatment time reduction was
highly advantageous allowing more  ﬂexibility of treating
radiosurgery patients without altering the regular daily work
schedule.
Use of RapidArc® for conventional fractionation, SRS,
and SBRT improved the efﬁciency of our radiation ther-
apy practice with great patient acceptance. This technology
also improves cost-effectiveness compared with other more
time-consuming radiation techniques. These beneﬁts may
potentially represent signiﬁcant cost savings for our health-
care system while providing better access to radiation
treatments, increasing patient convenience, and boosting
quality of life for patients.
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